Endologix (Irvine, Calif.) drew wildly mixed reactions from analysts after reporting its proposed merger with competitor Trivascular Technologies (Santa Rosa, Calif.) in a cash and stock deal valued at $211 million. Both companies are players in the competitive endovascular aortic repair (EVAR) market. Read More
